Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Randomized trials in melanoma: an update.

Alexander M M Eggermont1

  • 1Erasmus Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, EA 3075, Rotterdam, the Netherlands. a.m.m.eggermont@erasmusmc.nl

Surgical Oncology Clinics of North America
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.

Ecancermedicalscience·2026
Same author

An updated European organization for research and treatment of cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for merkel cell carcinoma (MCC).

European journal of cancer (Oxford, England : 1990)·2026
Same author

Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.

JAMA network open·2026
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

No effective therapies exist for metastatic melanoma. New drug development and a deeper understanding of melanoma biology are crucial for advancing treatment options.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Metastatic melanoma currently lacks effective therapeutic strategies.
  • Established treatments like polychemotherapy and chemoimmunotherapy have failed to demonstrate survival benefits.
  • Vaccine therapies show limited efficacy in stage IV disease.

Purpose of the Study:

  • To highlight the urgent need for novel therapeutic agents in metastatic melanoma treatment.
  • To emphasize the importance of understanding the underlying biology of malignant melanoma.
  • To advocate for the strategic use of new drugs as first-line treatments.

Main Methods:

  • Review of current treatment modalities for metastatic melanoma.
  • Analysis of the limitations of existing polychemotherapy, chemoimmunotherapy, and vaccine approaches.

Related Experiment Videos

  • Discussion on the necessity of improved mechanistic understanding for drug development.

    • Main Results:

    • Current therapeutic options for metastatic melanoma are inadequate, offering no survival advantage.
    • Phase III trials have often proceeded without a clear understanding of drug mechanisms.
    • Significant gaps exist in comprehending the biological drivers of malignant melanoma.

    Conclusions:

    • New drug candidates should be prioritized as first-line treatments for metastatic melanoma.
    • Further research into the biology of malignant melanoma is essential for therapeutic advancement.
    • A mechanistic approach is critical for the successful design and execution of clinical trials.